365 related articles for article (PubMed ID: 23108408)
1. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
Kliese N; Gobrecht P; Pachow D; Andrae N; Wilisch-Neumann A; Kirches E; Riek-Burchardt M; Angenstein F; Reifenberger G; Riemenschneider MJ; Meese E; Panayotova-Dimitrova D; Gutmann DH; Mawrin C
Oncogene; 2013 Sep; 32(39):4712-20. PubMed ID: 23108408
[TBL] [Abstract][Full Text] [Related]
2. Functional significance of S6K overexpression in meningioma progression.
Surace EI; Lusis E; Haipek CA; Gutmann DH
Ann Neurol; 2004 Aug; 56(2):295-8. PubMed ID: 15293284
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-195 Functions as a Tumor Suppressor by Directly Targeting Fatty Acid Synthase in Malignant Meningioma.
Song LR; Li D; Weng JC; Li CB; Wang L; Wu Z; Zhang JT
World Neurosurg; 2020 Apr; 136():e355-e364. PubMed ID: 31927122
[TBL] [Abstract][Full Text] [Related]
4. KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas.
Tang H; Zhu H; Wang X; Hua L; Li J; Xie Q; Chen X; Zhang T; Gong Y
J Mol Cell Biol; 2017 Aug; 9(4):315-324. PubMed ID: 28651379
[TBL] [Abstract][Full Text] [Related]
5. The expression of disabled-2 is common reduced in meningiomas.
Zhang Z; Chen Y; Xie X; Tang J
Neurol India; 2014; 62(1):57-61. PubMed ID: 24608456
[TBL] [Abstract][Full Text] [Related]
6. A microRNA expression signature predicts meningioma recurrence.
Zhi F; Zhou G; Wang S; Shi Y; Peng Y; Shao N; Guan W; Qu H; Zhang Y; Wang Q; Yang C; Wang R; Wu S; Xia X; Yang Y
Int J Cancer; 2013 Jan; 132(1):128-36. PubMed ID: 22674195
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 inhibitors suppress meningioma growth in mouse models.
Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
[TBL] [Abstract][Full Text] [Related]
9. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
Tummalapalli P; Gondi CS; Dinh DH; Gujrati M; Rao JS
Int J Oncol; 2007 Jul; 31(1):5-17. PubMed ID: 17549400
[TBL] [Abstract][Full Text] [Related]
10. Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin.
Utsuki S; Oka H; Sato Y; Kawano N; Tsuchiya B; Kobayashi I; Fujii K
Clin Neuropathol; 2005; 24(1):8-12. PubMed ID: 15696778
[TBL] [Abstract][Full Text] [Related]
11. Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth.
McCutcheon IE; Friend KE; Gerdes TM; Zhang BM; Wildrick DM; Fuller GN
J Neurosurg; 2000 Feb; 92(2):306-14. PubMed ID: 10659019
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
13. The transmembrane chemokines CXCL16 and CX3CL1 and their receptors are expressed in human meningiomas.
Li G; Hattermann K; Mentlein R; Mehdorn HM; Held-Feindt J
Oncol Rep; 2013 Feb; 29(2):563-70. PubMed ID: 23229614
[TBL] [Abstract][Full Text] [Related]
14. Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.
Kondraganti S; Gondi CS; Gujrati M; McCutcheon I; Dinh DH; Rao JS; Olivero WC
Int J Oncol; 2006 Jul; 29(1):25-32. PubMed ID: 16773181
[TBL] [Abstract][Full Text] [Related]
15. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?
Sayagués JM; Tabernero MD; Maíllo A; Espinosa A; Rasillo A; Díaz P; Ciudad J; López A; Merino M; Gonçalves JM; Santos-Briz A; Morales F; Orfao A
J Mol Diagn; 2004 Nov; 6(4):316-25. PubMed ID: 15507670
[TBL] [Abstract][Full Text] [Related]
17. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
van de Nes JA; Griewank KG; Schmid KW; Grabellus F
Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
[TBL] [Abstract][Full Text] [Related]
19. Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs.
Ludwig N; Kim YJ; Mueller SC; Backes C; Werner TV; Galata V; Sartorius E; Bohle RM; Keller A; Meese E
Neuro Oncol; 2015 Sep; 17(9):1250-60. PubMed ID: 25681310
[TBL] [Abstract][Full Text] [Related]
20. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
